Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 14, 2005

View Archived Issues

Caveolin-1 binding domain of HIV-1 gp41 as an epitope for a vaccine candidate/News in Context

sanofi-aventis reaffirms commitment to VEGF Trap alliance with Regeneron

Remune completes phase II studies in Italy, Spain

Safinamide shows promise in restless legs syndrome pilot study

Sunesis extends Cathepsin S inhibitor collaboration with Johnson & Johnson

TaiGen enters strategic alliance with P&G for antibiotic compound

Campral available in U.S.

BioAxone cleared to commence U.S. clinical development of Cethrin

Manufacturing milestone towards IND filing for PSA-PAH1

Enrollment begins in phase III Alzheimer's study of Flurizan

SPA for Avanir's phase III study of Neurodex

Positive phase IIa data for subset of patients treated with Miraxion

Positive data for oral Rambazole in psoriasis

Phase IIa data show utility of oral azoline in superficial fungal infections

FAS-20013 to enter clinical trials in TB and multidrug-resistant TB this year

Phase III study of long-acting injectable paliperidone palmitate in schizophrenia

KRX-101 phase II/III program recommended to continue to phase III

PEGylated integrin alpha4beta1 inhibitor with improved pharmacokinetic and pharmacodynamic profiles

Dextofisopam reported effective and well tolerated in IBS

PET scans provide new data on the effects of EMD-281014 in brain

Two clinical studies support the use of recombinant human albumin as an alternative to HSA

Phase III data on the effects of peginterferon alfa-2b plus ribavirin in HIV-HCV coinfection

MRS-2365: a novel, potent and selective P2Y1 receptor agonist

Nicotinic acetylcholine alpha7 receptor agonist with potential for the treatment of schizophrenia

PDE4 inhibitors described by Merck Frosst

sanofi-aventis patent claims CCR2B receptor antagonists

A series of quinolones for the treatment of CNS disorders

Scientists at 3-Dimensional Pharmaceuticals present novel protein tyrosine kinase inhibitors

Pfizer researchers report discovery of compounds with utility in diagnosis of CNS disorders

A series of antibacterial compounds described in patent literature

AstraZeneca prepares and tests vanilloid receptor antagonists